Belite Bio, Inc (BLTE) Free cash flow
- Free cash flow · 12 months (USD): Value $-37.06M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2025-12-31..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2025-12-31..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2025-12-31..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2025-12-31..
Free cash flow
Overview →Financial period ending 2025-12-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-37.06M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2025-12-31. $-36.99M − $71.00K ≈ $-37.06M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2025-12-31. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2025-12-31. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2025-12-31. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2025-12-31. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-36.99M | Cash generated by operating activities. Period ending 2025-12-31. |
| Operating cash flow / net income · 12 months | 0.48× | Operating cash flow / net income. Period ending 2025-12-31. $-36.99M ÷ $-77.61M ≈ 0.48× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -36.99M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 71.00K USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -37.06M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | (m) | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -77.61M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $-37.06M | (m) | $-36.99M | $71.00K | (m) | (m) | (m) | $-77.61M | (m) | (m) | (m) | 0.48× |
| 2024-12-31 | $-29.35M | (m) | $-29.23M | $116.00K | (m) | (m) | (m) | $-36.14M | (m) | (m) | (m) | 0.81× |
| 2023-12-31 | $-29.90M | (m) | $-29.84M | $63.00K | (m) | (m) | (m) | $-31.63M | (m) | (m) | (m) | 0.94× |
| 2022-12-31 | $-11.85M | (m) | $-11.46M | $394.00K | (m) | (m) | (m) | $-12.65M | (m) | (m) | (m) | 0.91× |
| 2021-12-31 | $-7.55M | (m) | $-7.47M | $74.00K | (m) | (m) | (m) | $-9.67M | (m) | (m) | (m) | 0.77× |
| 2020-12-31 | (m) | (m) | $-4.44M | (m) | (m) | (m) | (m) | $-5.75M | (m) | (m) | (m) | 0.77× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.